---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-264644"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:38:16.320530+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Stoke Q3 net loss $38.3M ($0.65/sh); Phase 3 EMPEROR >20 randomized

## Summary
- Net loss $38.3M ($0.65/sh) vs $26.4M ($0.47) in Q3 2024; revenue $10.6M vs $4.9M.
- Cash $328.6M as of Sep 30; $48.7M from Oct share sales; funded to mid-2028.
- Phase 3 EMPEROR: >20 patients randomized, ~35 in screening; enrollment on track for H2 2026.
- FDA meeting planned before year-end to discuss expedited regulatory pathways for zorevunersen.
- Ian F. Smith appointed permanent CEO (was interim); Arthur Tzianabos resumes Chairman role.

## SEC filing metadata
- accession: 0001193125-25-264644
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312525264644/0001193125-25-264644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312525264644/stok-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-264644
- JSON: https://secwatch.observer/filing/0001193125-25-264644.json
- Plain text: https://secwatch.observer/filing/0001193125-25-264644.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.